Holen Sie sich die Stockscreener-App
5.45
5.38%
-0.31
Handel nachbörslich:
5.45
Sagimet Biosciences Inc Aktie (SGMT) Neueste Nachrichten
Sagimet Biosciences (SGMT) Projected to Post Earnings on Wednesday - MarketBeat
Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf. - Defense World
Bull Bear: How does Sagimet Biosciences Inc score in quality rankings2025 Macro Impact & Consistent Profit Alerts - baoquankhu1.vn
SGMT Should I Buy - Intellectia AI
SGMT: Lead FASN inhibitor advances in MASH and acne, with pivotal trials and regulatory milestones ahead - TradingView
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences - The Manila Times
Sagimet Biosciences to Participate in Upcoming Investor Conferences in March 2026 - Quiver Quantitative
Biotech Sagimet lines up three March investor conferences - Stock Titan
SGMT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
SGMTSagimet Biosciences Inc. Latest Stock News & Market Updates - Stock Titan
Sagimet (NASDAQ: SGMT) CMO receives 88,000-share option and 44,000 RSUs - Stock Titan
Sagimet Biosciences (SGMT) CFO awarded 88,000 options and 44,000 RSUs - Stock Titan
What is the long term forecast for Sagimet Biosciences Inc. stockChart Signals & Short-Term Swing Trade Alerts - mfd.ru
Can Sagimet Biosciences Inc. continue delivering strong returnsTrade Volume Report & Smart Money Movement Alerts - mfd.ru
Sagimet (SGMT) CEO granted 256k options and 128k RSUs in Form 4 - Stock Titan
Growth Value: Is Sagimet Biosciences Inc in a consolidation phaseJuly 2025 Retail & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Sagimet Biosciences (NASDAQ:SGMT) vs. AC Immune (NASDAQ:ACIU) Financial Survey - Defense World
Don't Ignore The Insider Selling In Sagimet Biosciences - simplywall.st
Sagimet Biosciences Showcases FASN Strategy, MASH Phase II Timeline and Acne Data at Guggenheim Conference - MarketBeat
Will Sagimet Biosciences Inc. face regulatory challengesWeekly Loss Report & Safe Entry Momentum Stock Tips - mfd.ru
Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero - MSN
Top Sagimet Executives Quietly Unload Shares in Coordinated Insider Move - TipRanks
David Happel Sells 12,101 Shares of Sagimet Biosciences (NASDAQ:SGMT) Stock - MarketBeat
Is Sagimet Biosciences Inc. stock trending bullish2025 Volume Leaders & Free Safe Capital Growth Stock Tips - mfd.ru
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences - The Manila Times
Hear Sagimet Biosciences at Guggenheim and Oppenheimer investor events - Stock Titan
A Look At Sagimet Biosciences (SGMT) Valuation After Denifanstat’s Phase 3 Acne Trial Success - Yahoo Finance
Analysts Are Bullish on These Healthcare Stocks: Thermo Fisher (TMO), Tenet Healthcare (THC) - The Globe and Mail
Sagimet Biosciences (NASDAQ:SGMT) Coverage Initiated by Analysts at Guggenheim - Defense World
After Clearing Up Acne, Sagimet Stock Rises - Barron's
Sagimet a new buy at Guggenheim on promise of MASH, acne asset - Seeking Alpha
Sagimet Biosciences (NASDAQ:SGMT) Earns Buy Rating from Analysts at Guggenheim - MarketBeat
Sagimet Biosciences' (SGMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
New acne mechanism shows 1-year durability in Phase III, says Sagimet - The Pharma Letter
Sagimet Therapeutics: Strengthened FASN-Inhibition Safety Profile and Advancing Phase 2 Programs Support Buy Rating - TipRanks
Sagimet stock rises after positive Phase 3 safety data for acne drug By Investing.com - Investing.com South Africa
Sagimet stock rises after positive Phase 3 safety data for acne drug - Investing.com Australia
Sagimet Biosciences announces license partner Ascletis issues results for ASC40 - TipRanks
Sagimet Biosciences Reports Positive Phase 3 Acne Data - TipRanks
Sagimet Biosciences Inc Announces Positive Phase 3 Acne Trial Results - TradingView
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne - The Manila Times
Sagimet’s Denifanstat: China Phase III Safety Data Isn’t A Negative Signal (NASDAQ:SGMT) - Seeking Alpha
Sagimet down as Chinese partner posts late-stage trial data for acne therapy - MSN
Sagimet Biosciences (NASDAQ:SGMT) Stock Rating Upgraded by Barclays - MarketBeat
Once-a-day acne pill shows 40-week safety in 240 Chinese patients - stocktitan.net
Barclays Initiates Coverage of Sagimet Biosciences (SGMT) with Equal-Weight Recommendation - Nasdaq
Barclays Initiates Coverage on Sagimet Biosciences With Equal Weight Rating, $8 Price Target - marketscreener.com
Is Sagimet Biosciences Inc stock influenced by commodity pricesWeekly Profit Analysis & Reliable Breakout Forecasts - baoquankhu1.vn
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Sagimet Biosciences enters global license agreement with TAPI - MSN
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Sagimet Biosciences (NASDAQ:SGMT) Shares Down 0.5%Here's Why - MarketBeat
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):